Journal
ONCOTARGET
Volume 6, Issue 38, Pages 41339-41349Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.5463
Keywords
primary hepatocellular carcinoma; autologous tumor-infiltrating lymphocytes; adoptive cell therapy
Categories
Funding
- Guangdong Province Science and Technology Plan Project, China [2011A030400004]
- Gillson Longenbaugh Foundation
Ask authors/readers for more resources
This report describes an ongoing Phase I clinical trial testing the safety of adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) in patients with primary hepatocellular carcinoma (HCC). Fifteen HCC patients were treated with their activated and expanded TILs following tumor resection. From a total of 17 patients with HCC, TIL were successfully expanded from 15 patients (88%), whereas two patients showed minimal or no expansion of TIL. Transient increase in the frequency of T cells was observed after adoptive transfer who was found only associated with grade I flu-like symptoms and malaise. After a median follow-up of 14 months, 15 patients (100%) were alive; and 12 patients (80%) showed no evidence of disease, 3 patients (patient 1,11,12) had tumor recurrence. The time to the diagnosis of tumor recurrence following therapy ranged from 105 to 261 days. These results indicate that immunotherapy with activated and expanded autologous TIL could be successfully performed with low toxicity, thus would serve as a novel treatment modality for patients with HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available